Dr. DeZern is a Professor of Oncology and Medicine at The Johns Hopkins University School of Medicine. She is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. DeZern has expertise in aplastic anemia, myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, acute myeloid leukemia, and bone marrow transplantation. Dr. DeZern received her medical degree at The Johns Hopkins University School of Medicine. She completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology and hematology, as well as obtained a Masters in Clinical Investigations at the Bloomberg School of Public health. Dr. DeZern is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. Dr. DeZern’s principle research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of bone marrow failure (aplastic anemia and myelodysplastic syndromes). She has specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes. Additionally, she has taken a rigorous approach to the study of diagnostics and supportive case (such as transfusion practices) in these patient populations. She is or has been the Principal Investigator for a number of multicenter trials in collaboration with the MDS Clinical Research Consortium, the Eastern Co-operative Oncology Group (ECOG)-ACRIN and now the Bone Marrow Trials Clinical Trials Network (BMTCTN). She is the Study Chair for the multi-site BMTCTN study (CHAMP) investigating the role of haploidentical donor transplantation using post-transplantation cyclophosphamide in patients with relapsed several aplastic anemia. Dr. DeZern is the local PI as well as the Deputy Chair for The National MDS Study, a collaborative natural history study of the NHLBI and the NCI. As a clinical investigator with a focus on translation of novel treatments to the clinic, Dr. DeZern’s goal is to improve outcomes for patients with bone marrow failure at the bedside and in her research environment. Dr. Dezern is rated as a Distinguished provider by MediFind in the treatment of Fanconi Anemia. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Moonjung Jung is an Assistant Professor of Medicine at the Johns Hopkins University School of Medicine. Dr. Jung graduated Summa Cum Laude from Ewha Womans University College of Medicine in Seoul, South Korea. She then completed the Internal Medicine residency training at Houston Methodist Hospital, Weill Cornell Medical College, Houston, TX and the Hematology and Medical Oncology fellowship training at National Institutes of Health, Bethesda, MD. In 2016, Dr. Jung joined the Rockefeller University as an Instructor in Clinical investigation. She received M.S. in Clinical Investigation from the Rockefeller University. In 2021, Dr. Jung joined the Johns Hopkins University School of Medicine as faculty in the Division of Hematology. Dr. Jung is rated as a Distinguished provider by MediFind in the treatment of Fanconi Anemia. Her top areas of expertise are Fanconi Anemia, Congenital Aplastic Anemia, Aplastic Anemia, and Anemia.

Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023. Dr. Brodsky is rated as an Advanced provider by MediFind in the treatment of Fanconi Anemia. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy.

Dr. Ivana Gojo is a Hematologist/Oncologist in Baltimore. Her clinical focus is on diagnosis and management of patients with acute leukemias (AML, ALL) and other myeloid malignancies (MDS, MPNs, CML), with emphasis on the development of novel therapeutic approaches for these diseases. She is nationally and internationally recognized expert in clinical translation of novel therapeutics for acute leukemias and principal investigator on multiple multi-center investigator-initiated studies. Dr. Gojo joined the Johns Hopkins faculty in 2012 as the Co-Director of Leukemia Drug Development Program. She has served on the National Cancer Institute (NCI) Investigational Drug Steering Committee since 2014. Dr. Gojo received a Service Star Award from Johns Hopkins Medicine Service Excellence in 2018 for her exemplary care of leukemia patients. Dr. Gojo contributed to the clinical translational and drug development effort of multiple novel agents targeting pathogenic pathways in patients with acute leukemia. Her research efforts are now concentrated on the development and integration of novel immunotherapies into therapeutic armamentarium for patients with acute leukemia. She mentors basic and clinical research fellows and junior faculty on the development and design of novel clinical trials and mechanistic laboratory studies associated with these trials. She served as a leukemia team leader on the National Institute of Health (NIH)/NCI N01 grant (Phase II consortium) (2009-2011), and is co-principal investigator (PI) on the Experimental Therapeutics (ET)-Clinical Trial Network (CTN) UM1 grant supporting early clinical trials. Dr. Gojo has served on the National Comprehensive Cancer Network guideline panel for AML since 2019, Myeloid Growth Factor guideline panel since 2015 and previously served on the MPNs guideline panel (2016-2019). She has extensive experience in the regulatory aspects of drug development and served as the Chair (2015-2016) and Co-Chair (2014-2015) of the Cancer Research Review Committee at Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, and serves as a member of the SKCCC Biostatistics Core Advisory Committee and SKCCC Clinical Research Office Coordinating Center Oversight Committee. Dr. Gojo is rated as an Experienced provider by MediFind in the treatment of Fanconi Anemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Dr. Rakhi P. Naik is the Associate Director for the Division of Hematology at Johns Hopkins University. She also serves as Director of the Fellowship Hematology Track and Director of Organ Systems Foundation of Medicine (OSFM), the largest pre-clerkship course in the medical school. She holds an undergraduate degree in Biomedical & Electrical Engineering from Duke University, an M.D. with. Dr. Naik is rated as an Advanced provider by MediFind in the treatment of Fanconi Anemia. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Hemoglobinopathy.

Vu Duong is a Hematologist Oncology specialist and a Hospital Medicine provider in Baltimore, Maryland. Dr. Duong is rated as an Advanced provider by MediFind in the treatment of Fanconi Anemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Myringotomy.

Sandrine Niyongere is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Niyongere is rated as an Experienced provider by MediFind in the treatment of Fanconi Anemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, and Bone Marrow Aspiration.

Bonnie Lau is a Pediatric Hematologist Oncology provider in Baltimore, Maryland. Dr. Lau is rated as an Experienced provider by MediFind in the treatment of Fanconi Anemia. Her top areas of expertise are Shwachman-Diamond Syndrome, Aplastic Anemia, Fanconi Anemia, and Congenital Aplastic Anemia.

Lukasz Gondek is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Gondek is rated as an Experienced provider by MediFind in the treatment of Fanconi Anemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Monoblastic Leukemia (AmoL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Gondek is currently accepting new patients.

Jennifer Yui is a Hematologist in Baltimore, Maryland. Dr. Yui is rated as an Experienced provider by MediFind in the treatment of Fanconi Anemia. Her top areas of expertise are Thrombocytopenia, Myeloproliferative Neoplasms (MPN), Hemolytic Anemia, Splenectomy, and Bone Marrow Aspiration. Dr. Yui is currently accepting new patients.

Michael Streiff is a Hematologist in Baltimore, Maryland. Dr. Streiff is rated as an Experienced provider by MediFind in the treatment of Fanconi Anemia. His top areas of expertise are Venous Thromboembolism (VTE), Deep Vein Thrombosis, Pulmonary Embolism, Pancreaticoduodenectomy, and Bone Marrow Aspiration.

Suman Rao is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Rao is rated as an Experienced provider by MediFind in the treatment of Fanconi Anemia. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC). Dr. Rao is currently accepting new patients.